Y-Mabs Therapeutics Inc (NASDAQ: YMAB) kicked off on Friday, down -0.32% from the previous trading day, before settling in for the closing price of $6.18. Over the past 52 weeks, YMAB has traded in a range of $6.01-$20.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 46.29% over the last five years. While this was happening, its average annual earnings per share was recorded -27.74%. With a float of $37.22 million, this company’s outstanding shares have now reached $44.77 million.
The firm has a total of 100 workers. Let’s measure their productivity. In terms of profitability, gross margin is 88.83%, operating margin of -33.66%, and the pretax margin is -27.28%.
Y-Mabs Therapeutics Inc (YMAB) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Y-Mabs Therapeutics Inc is 16.91%, while institutional ownership is 60.22%. The most recent insider transaction that took place on Sep 13 ’24, was worth 875,550. In this transaction CHIEF BUSINESS OFFICER of this company sold 65,000 shares at a rate of $13.47, taking the stock ownership to the 97,681 shares. Before that another transaction happened on Sep 16 ’24, when Company’s CHIEF BUSINESS OFFICER sold 30,000 for $12.97, making the entire transaction worth $389,100. This insider now owns 67,681 shares in total.
Y-Mabs Therapeutics Inc (YMAB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.74% per share during the next fiscal year.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Trading Performance Indicators
Take a look at Y-Mabs Therapeutics Inc’s (YMAB) current performance indicators. Last quarter, stock had a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Y-Mabs Therapeutics Inc (YMAB)
Analysing the last 5-days average volume posted by the [Y-Mabs Therapeutics Inc, YMAB], we can find that recorded value of 0.42 million was better than the volume posted last year of 0.38 million. As of the previous 9 days, the stock’s Stochastic %D was 9.43%. Additionally, its Average True Range was 0.57.
During the past 100 days, Y-Mabs Therapeutics Inc’s (YMAB) raw stochastic average was set at 1.49%, which indicates a significant decrease from 5.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.75% in the past 14 days, which was lower than the 61.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.94, while its 200-day Moving Average is $12.44. Now, the first resistance to watch is $6.30. This is followed by the second major resistance level at $6.45. The third major resistance level sits at $6.57. If the price goes on to break the first support level at $6.03, it is likely to go to the next support level at $5.91. Now, if the price goes above the second support level, the third support stands at $5.76.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Key Stats
The company with the Market Capitalisation of 275.90 million has total of 44,789K Shares Outstanding. Its annual sales at the moment are 84,820 K in contrast with the sum of -21,430 K annual income. Company’s last quarter sales were recorded 18,460 K and last quarter income was -7,000 K.
